Cohance Lifesciences Intrinsic Value
Cohance Lifesciences (COHANCE) median intrinsic value is ₹703.61 from 8 valuation models (range ₹125–₹1043), vs current price ₹417.10 — +68.7% upside (Trading Below Calculated Value), margin of safety 40.7%. Analyse Cohance Lifesciences ownership pattern to track promoter, FII and institutional holdings.
COHANCE Valuation Methods Summary — DCF, Graham Number & P/E
Cohance Lifesciences intrinsic value across 8 models vs current price ₹417.10 — upside/downside and value range per method. For current market price and key ratios, visit Cohance Lifesciences share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹125.13 | ₹100.10 - ₹150.16 | -70.0% | EPS: ₹2.04, Sector P/E: 22x |
| Book Value Method | asset | ₹1042.75 | ₹938.48 - ₹1147.03 | +150.0% | Book Value/Share: ₹1029.21, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹834.20 | ₹750.78 - ₹917.62 | +100.0% | Revenue/Share: ₹649.47, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹834.20 | ₹750.78 - ₹917.62 | +100.0% | EBITDA: ₹320.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹703.61 | ₹562.89 - ₹844.33 | +68.7% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹125.13 | ₹112.62 - ₹137.64 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹125.13 | ₹112.62 - ₹137.64 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| Graham Defensive Method | conservative | ₹217.35 | ₹195.62 - ₹239.09 | -47.9% | EPS: ₹2.04, BVPS: ₹1029.21 |
COHANCE Intrinsic Value vs Market Price — All Valuation Models
Cohance Lifesciences fair value range ₹125–₹1043 vs current market price ₹417.10 across 8 valuation models. Read COHANCE dividend payout details for the complete payout history and dividend yield track record.
COHANCE Intrinsic Value Analysis — Undervalued or Overvalued?
Cohance Lifesciences median intrinsic value ₹703.61, current price ₹417.10 — Trading Below Calculated Value by 68.7%, margin of safety 40.7%.
What is the intrinsic value of COHANCE?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Cohance Lifesciences (COHANCE) is ₹703.61 (median value). With the current market price of ₹417.10, this represents a +68.7% variance from our estimated fair value.
The valuation range spans from ₹125.13 to ₹1042.75, indicating ₹125.13 - ₹1042.75.
Is COHANCE undervalued or overvalued?
Based on our multi-method analysis, Cohance Lifesciences (COHANCE) appears to be trading below calculated value by approximately 68.7%.
COHANCE Financial Health — Key Ratios vs Industry Benchmarks
Cohance Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 1.71 | Industry Standard: 2.0+ | Above 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 0.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 13.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.43x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
COHANCE Cash Flow Quality — Operating & Free Cash Flow
Cohance Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹288 Cr | ₹162 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹359 Cr | ₹178 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹457 Cr | ₹360 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹330 Cr | ₹262 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹383 Cr | ₹228 Cr | Positive Free Cash Flow | 8/10 |